Novartis Ag (NVS) Non-Current Deferred Tax Liability (2016 - 2026)
Novartis Ag's Non-Current Deferred Tax Liability history spans 12 years, with the latest figure at -$2.5 billion for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to -$2.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.5 billion, a N/A change, with the full-year FY2025 number at $3.4 billion, up 525.16% from a year prior.
- Non-Current Deferred Tax Liability hit -$2.5 billion in Q1 2026 for Novartis Ag, down from $3.4 billion in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for NVS hit a ceiling of $3.4 billion in Q4 2025 and a floor of -$2.5 billion in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $915.2 million across 5 years, with a median of $270.0 million in 2023.
- Biggest five-year swings in Non-Current Deferred Tax Liability: plummeted 790.32% in 2022 and later surged 525.16% in 2025.
- Tracing NVS's Non-Current Deferred Tax Liability over 5 years: stood at $2.7 billion in 2022, then crashed by 117.65% to -$474.0 million in 2023, then plummeted by 68.57% to -$799.0 million in 2024, then surged by 525.16% to $3.4 billion in 2025, then tumbled by 173.59% to -$2.5 billion in 2026.
- Business Quant data shows Non-Current Deferred Tax Liability for NVS at -$2.5 billion in Q1 2026, $3.4 billion in Q4 2025, and $2.3 billion in Q2 2025.